| http://purl.uniprot.org/citations/19551853 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/19551853 | http://www.w3.org/2000/01/rdf-schema#comment | "The methylation status of cystatin M (CST6) gene in breast tumors was investigated and its prognostic significance as a novel breast cancer biomarker was evaluated. Using methylation-specific PCR (MSP), CST6 promoter methylation was examined in 134 formalin fixed paraffin-embedded tissues (FFPEs): 10 pairs of breast tumors and their surrounding normal tissues, 10 breast fibroadenomas, 11 normal breast tissues and 93 breast tumors. Methylation of CST6 promoter was observed in 2/21 (9.5%) noncancerous breast tissues, 1/10 (10%) benign breast tumors (fibroadenomas) and 52 (55.9%) operable breast cancer tumor samples. CST6 was rarely methylated in the normal tissue surrounding the tumor (10%). During the follow-up period, 24 (25.8%) patients relapsed and 19 (20.4%) died. CST6 methylation was detected in 19 (79.2%) of patients who relapsed and in 15 (78.9%) of patients who died. Disease-free-interval (DFI) and overall survival (OS) were significantly associated with CST6 promoter methylation (p=0.004 and p=0.001 respectively). Multivariate analysis revealed that CST6 methylation is an independent prognostic factor for DFI (HR=3.484; 95% CI: 1.155-10.511; p=0.027). and OS (HR=9.190; 95% CI: 1.989-42.454; p=0.004). CST6 promoter methylation status in tumor cells seems to provide important prognostic information in operable breast cancer and merits to be further evaluated and validated in a larger cohort of patients."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.org/dc/terms/identifier | "doi:10.1002/ijc.24686"xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/author | "Sotiropoulou G."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/author | "Kaklamanis L."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/author | "Georgoulias V."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/author | "Lianidou E.S."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/author | "Mavroudis D."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/author | "Balkouranidou I."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/author | "Kioulafa M."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/date | "2009"xsd:gYear |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/name | "Int J Cancer"xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/pages | "2887-2892"xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/title | "Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer."xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://purl.uniprot.org/core/volume | "125"xsd:string |
| http://purl.uniprot.org/citations/19551853 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/19551853 |
| http://purl.uniprot.org/citations/19551853 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/19551853 |
| http://purl.uniprot.org/uniprot/#_Q15828-mappedCitation-19551853 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/19551853 |
| http://purl.uniprot.org/uniprot/#_Q6IBD2-mappedCitation-19551853 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/19551853 |
| http://purl.uniprot.org/uniprot/Q6IBD2 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/19551853 |
| http://purl.uniprot.org/uniprot/Q15828 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/19551853 |